The multiple dose antagonist protocol using Cetrorelix (Cetritide®) offers a new way of controlled ovarian stimulation for assisted reproductive techniques;Cetrorelix (Cetrotide®) im Mehrfachgabe-Protokoll zur ovariellen Stimulation bei der IVF

Reproduktionsmedizin

Volumn 16, Issue 6, 2000, Pages 390-399

  Ludwig, M ^a   Felberbaum, R E ^a   Diedrich, K ^a   Hamm, W ^b   Riethmuller Winzen H ^b   Ulrich, H ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b ASTA MEDICA AG   (Germany)

Author keywords

Cetrorelix; GnRH antagonist; Multiple dose protocol; Ovarian hyperstimulation syndrome

Indexed keywords

CETRORELIX;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG SAFETY; DRUG TOLERABILITY; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; OOCYTE; OVARY DISEASE; OVARY HYPERSTIMULATION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL;

EID: 0034533277     PISSN: 14346931     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004440000227     Document Type: Article

References (33)

1. Controlled ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the GnRH-antagonist Cetrorelix (Cetrotide®) and the GnRH-agonist Buserelin
2. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation
3. Optimal protocol for gonadotropin releasing hormone agonist use in ovarian stimulation
4. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction
5. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation
6. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women
7. Time to revolutionize ovarian stimulation
8. The pathophysiology of ovarian hyperstimulation syndrome - Views and ideas
9. Minimal ovarian stimulation for IVF: Appraisal of potential benefits and drawbacks
10. Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antogonist Cetrorelix at different dosages
11. Controlled ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH-antagonist Cetrorelix (Cetrotide®) according to the multiple dose protocol - Results of a prospective non controlled phase III study
12. Are we on the verge of a new era in ART?
13. An overview of ovarian hyperstimulation syndrome: A reproductive medicine-iatrogenic disease picture with internal medicine consequences
14. Plasma and follicular fluid concentrations of GnRH antagonist Cetrorelix after multiple application of different doses for the hormonal stimulation in IVF cycles
15. Myocardial infarction associated with ovarian hyperstimulation syndrome
16. Deep vein thrombosis during administration of HMG for ovarian stimulation
17. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the GnRH antagonist Cetrorelix (Cetrotide®) in controlled ovarian stimulation for assisted reproduction
18. The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg
19. A prospective randomized controlled study in IVF-ET with a single dose of a LH-RH antagonist (Cetrorelix) or a depot formula of a LH-RH ogonist (Triptorelin)
20. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: A pilot study
21. The single or dual administration of the GnRH antagonist Cetrorelix prevents premature LH surges in an IVF-ET program
22. Friendly IVF: The way of the future?
23. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins
24. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): A pilot study with minimal stimulation
25. Seven-day administration of the gonadotropin-releasing hormone antagonist Cetrorelix in normal cycling women
26. Reduced in vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase
27. Gonadotrophine-releasing hormone agonists in assisted reproductive therapy
28. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective safe and convenient: Results of a controlled randomized multicentre trial
29. A double-blind randomized dose-finding study to assess the efficacy of the gonadothropin-releasing hormone antagonist ganirelix (Org 37 462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulation with recombinant follicle stimulating hormone (Puregon®)
30. Agents stimulating gonadal function in human
31. Never on a sunday: Programming for IVF - ET and GIFT